PL364081A1 - Zastosowanie odwrotnych agonistów GABA[A] w kombinacji z częściowymi agonistami receptora nikotyny,estrogenem, selektywnymi modulatorami estrogenu lub witaminą E do leczenia zaburzeń poznawczych - Google Patents

Zastosowanie odwrotnych agonistów GABA[A] w kombinacji z częściowymi agonistami receptora nikotyny,estrogenem, selektywnymi modulatorami estrogenu lub witaminą E do leczenia zaburzeń poznawczych

Info

Publication number: PL364081A1
Authority: PL; Poland
Prior art keywords: estrogen; agonists; gaba; vitamin; treatment
Prior art date: 2001-03-01

Application number

PL02364081A

Other languages

English (en)

Inventor

Anabella Villalobos

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-01

Filing date

2002-02-20

Publication date

2004-12-13

2002-02-20 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-12-13 Publication of PL364081A1 publication Critical patent/PL364081A1/pl

Links

229940011871 estrogen Drugs 0.000 title 2
239000000262 estrogen Substances 0.000 title 2
239000000556 agonist Substances 0.000 title 1
208000010877 cognitive disease Diseases 0.000 title 1
229960002715 nicotine Drugs 0.000 title 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title 1
239000004031 partial agonist Substances 0.000 title 1
229940088594 vitamin Drugs 0.000 title 1
229930003231 vitamin Natural products 0.000 title 1
235000013343 vitamin Nutrition 0.000 title 1
239000011782 vitamin Substances 0.000 title 1
150000003722 vitamin derivatives Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PL02364081A 2001-03-01 2002-02-20 Zastosowanie odwrotnych agonistów GABA[A] w kombinacji z częściowymi agonistami receptora nikotyny,estrogenem, selektywnymi modulatorami estrogenu lub witaminą E do leczenia zaburzeń poznawczych PL364081A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27256601P	2001-03-01	2001-03-01
PCT/IB2002/000515 WO2002069948A1 (en)	2001-03-01	2002-02-20	Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Publications (1)

Publication Number	Publication Date
PL364081A1 true PL364081A1 (pl)	2004-12-13

Family

ID=23040351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02364081A PL364081A1 (pl)	2001-03-01	2002-02-20	Zastosowanie odwrotnych agonistów GABA[A] w kombinacji z częściowymi agonistami receptora nikotyny,estrogenem, selektywnymi modulatorami estrogenu lub witaminą E do leczenia zaburzeń poznawczych

Country Status (33)

Country	Link
US (2)	US20020193360A1 (pl)
EP (1)	EP1363606A1 (pl)
JP (1)	JP2004527500A (pl)
KR (1)	KR20030076717A (pl)
CN (1)	CN1494422A (pl)
AP (1)	AP2002002465A0 (pl)
AR (1)	AR033425A1 (pl)
BG (1)	BG108131A (pl)
BR (1)	BR0207802A (pl)
CA (1)	CA2439581A1 (pl)
CR (1)	CR7059A (pl)
CZ (1)	CZ20032338A3 (pl)
DO (1)	DOP2002000345A (pl)
EA (1)	EA200300854A1 (pl)
EC (1)	ECSP034759A (pl)
EE (1)	EE200300422A (pl)
GT (1)	GT200200039A (pl)
HU (1)	HUP0303448A3 (pl)
IL (1)	IL157465A0 (pl)
IS (1)	IS6905A (pl)
MA (1)	MA26999A1 (pl)
MX (1)	MXPA03007834A (pl)
NO (1)	NO20033821L (pl)
NZ (1)	NZ527397A (pl)
OA (1)	OA12554A (pl)
PA (1)	PA8540701A1 (pl)
PE (1)	PE20020927A1 (pl)
PL (1)	PL364081A1 (pl)
SK (1)	SK10752003A3 (pl)
TN (1)	TNSN02018A1 (pl)
UY (1)	UY27188A1 (pl)
WO (1)	WO2002069948A1 (pl)
ZA (1)	ZA200306193B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050065205A1 (en) *	2002-03-07	2005-03-24	Daniel Alkon	Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en)	2002-03-07	2004-11-30	Blanchette Rockefeller Neurosciences Institute	Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) *	2002-03-07	2008-01-03	Alkon Daniel L	Methods for alzheimer's disease treatment and cognitive enhancement
US8030300B2 (en)	2003-06-10	2011-10-04	Georgetown University	Ligands for nicotinic acetylcholine receptors, and methods of making and using them
TW200538181A (en)	2004-05-18	2005-12-01	Brni Neurosciences Inst	Treatment of depressive disorders
US8510055B2 (en)	2005-08-03	2013-08-13	The Johns Hopkins University	Methods for characterizing and treating cognitive impairment in aging and disease
EP1924712B1 (en) *	2005-08-03	2018-10-03	The Johns Hopkins University	Methods for characterizing and treating cognitive impairment in aging and disease
DK2032987T3 (en)	2006-05-22	2016-04-25	Univ Leland Stanford Junior	Pharmacological treatment of Cognitive impairment
US10954231B2 (en)	2006-10-16	2021-03-23	Bionomics Limited	Anxiolytic compounds
CA2666219C (en) *	2006-10-16	2017-02-07	Bionomics Limited	Novel anxiolytic compounds
AU2013202426B2 (en) *	2006-10-16	2015-08-06	Bionomics Limited	Novel anxiolytic compounds
EP2121000B1 (en)	2007-02-09	2015-09-23	Blanchette Rockefeller Neurosciences, Institute	Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
WO2009143347A2 (en) *	2008-05-22	2009-11-26	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318695A1 (en) *	2008-06-19	2009-12-24	Vinod Kumar Kansal	Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) *	2008-07-10	2010-01-14	Revital Lifshitz-Liron	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US10206921B2 (en) *	2009-06-03	2019-02-19	The Regents Of The University Of California	Methods and compositions for treating a subject for central nervous system (CNS) injury
RU2012102052A (ru) *	2009-06-22	2013-11-20	Тева Фармасьютикал Индастриз Лтд.	Твердые формы солей варениклина и способы их получения
EP2640391B1 (en)	2010-11-15	2015-11-11	Agenebio, Inc.	Pyridazine derivatives, compositions and methods for treating cognitive impairment
JP2014510065A (ja)	2011-03-02	2014-04-24	バイオノミックスリミテッド	治療薬としての新規な小分子
US20140051701A1 (en) *	2011-03-02	2014-02-20	Bionomics Limited	Methods of treating a disease or condition of the central nervous system
CA2835450C (en)	2011-05-12	2020-05-12	Bionomics Limited	Methods for preparing naphthyridines
EP3083569B1 (en)	2013-12-20	2022-01-26	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
IL256354B (en)	2015-06-19	2022-09-01	Agenebio Inc	Benzodiazepine derivatives, compositions, and uses thereof for treating cognitive impairment
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt)	2016-12-19	2019-11-26	Agenebio, Inc.	derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
MX2020013927A (es)	2018-06-19	2021-03-02	Agenebio Inc	Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
CN116008442B (zh) *	2023-03-27	2023-06-30	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂的合成中间体的杂质检测方法
CN116077459B (zh) *	2023-04-10	2023-07-07	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂的胶囊剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI20270A (sl) *	1997-08-25	2000-12-31	Neurogen Corporation	Substituirani 4-okso-naftiridin-3-karboksamidi kot ligandi možganskih GABA receptorjev
US6448246B1 (en) *	1999-05-25	2002-09-10	Neurogen Corporation	Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands

2002
- 2002-02-20 MX MXPA03007834A patent/MXPA03007834A/es unknown
- 2002-02-20 PL PL02364081A patent/PL364081A1/pl not_active Application Discontinuation
- 2002-02-20 CN CNA028058046A patent/CN1494422A/zh active Pending
- 2002-02-20 EP EP02700509A patent/EP1363606A1/en not_active Withdrawn
- 2002-02-20 SK SK1075-2003A patent/SK10752003A3/sk not_active Application Discontinuation
- 2002-02-20 EE EEP200300422A patent/EE200300422A/xx unknown
- 2002-02-20 KR KR10-2003-7011366A patent/KR20030076717A/ko not_active Ceased
- 2002-02-20 OA OA1200300213A patent/OA12554A/en unknown
- 2002-02-20 JP JP2002569125A patent/JP2004527500A/ja active Pending
- 2002-02-20 IL IL15746502A patent/IL157465A0/xx unknown
- 2002-02-20 EA EA200300854A patent/EA200300854A1/ru unknown
- 2002-02-20 CA CA002439581A patent/CA2439581A1/en not_active Abandoned
- 2002-02-20 HU HU0303448A patent/HUP0303448A3/hu unknown
- 2002-02-20 NZ NZ527397A patent/NZ527397A/en unknown
- 2002-02-20 BR BR0207802-3A patent/BR0207802A/pt not_active IP Right Cessation
- 2002-02-20 WO PCT/IB2002/000515 patent/WO2002069948A1/en not_active Ceased
- 2002-02-20 CZ CZ20032338A patent/CZ20032338A3/cs unknown
- 2002-02-26 DO DO2002000345A patent/DOP2002000345A/es unknown
- 2002-02-26 PE PE2002000157A patent/PE20020927A1/es not_active Application Discontinuation
- 2002-02-26 US US10/083,743 patent/US20020193360A1/en not_active Abandoned
- 2002-02-27 UY UY27188A patent/UY27188A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100693A patent/AR033425A1/es not_active Application Discontinuation
- 2002-02-27 GT GT200200039A patent/GT200200039A/es unknown
- 2002-02-28 PA PA20028540701A patent/PA8540701A1/es unknown
- 2002-02-28 TN TNTNSN02018A patent/TNSN02018A1/fr unknown
- 2002-02-28 AP APAP/P/2002/002465A patent/AP2002002465A0/en unknown
2003
- 2003-08-07 IS IS6905A patent/IS6905A/is unknown
- 2003-08-11 ZA ZA200306193A patent/ZA200306193B/en unknown
- 2003-08-19 MA MA27286A patent/MA26999A1/fr unknown
- 2003-08-25 CR CR7059A patent/CR7059A/es not_active Application Discontinuation
- 2003-08-25 BG BG108131A patent/BG108131A/xx unknown
- 2003-08-28 NO NO20033821A patent/NO20033821L/no not_active Application Discontinuation
- 2003-09-01 EC EC2003004759A patent/ECSP034759A/es unknown
- 2003-12-02 US US10/727,934 patent/US20040082555A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PE20020927A1 (es)	2002-10-30
HUP0303448A3 (en)	2005-05-30
EA200300854A1 (ru)	2004-02-26
AR033425A1 (es)	2003-12-17
DOP2002000345A (es)	2002-12-15
US20020193360A1 (en)	2002-12-19
BG108131A (en)	2004-09-30
CN1494422A (zh)	2004-05-05
BR0207802A (pt)	2004-03-09
IS6905A (is)	2003-08-07
AP2002002465A0 (en)	2002-06-30
MA26999A1 (fr)	2004-12-20
WO2002069948A1 (en)	2002-09-12
OA12554A (en)	2006-06-07
ZA200306193B (en)	2004-08-11
GT200200039A (es)	2002-11-21
MXPA03007834A (es)	2003-12-08
ECSP034759A (es)	2003-10-28
CR7059A (es)	2004-03-10
CZ20032338A3 (cs)	2004-08-18
US20040082555A1 (en)	2004-04-29
JP2004527500A (ja)	2004-09-09
PA8540701A1 (es)	2002-09-30
EP1363606A1 (en)	2003-11-26
SK10752003A3 (sk)	2004-08-03
NO20033821L (no)	2003-09-10
EE200300422A (et)	2004-02-16
UY27188A1 (es)	2002-10-31
KR20030076717A (ko)	2003-09-26
NZ527397A (en)	2005-05-27
TNSN02018A1 (fr)	2005-12-23
IL157465A0 (en)	2004-03-28
NO20033821D0 (no)	2003-08-28
HUP0303448A2 (hu)	2004-01-28
CA2439581A1 (en)	2002-09-12

Legal Events

Date	Code	Title	Description
2010-08-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL364081A1 (pl)	2004-12-13	Zastosowanie odwrotnych agonistów GABA[A] w kombinacji z częściowymi agonistami receptora nikotyny,estrogenem, selektywnymi modulatorami estrogenu lub witaminą E do leczenia zaburzeń poznawczych
PT2266594E (pt)	2015-08-05	Vegf para utilização no tratamento de distúrbios do sistema nervoso central
IL158745A0 (en)	2004-05-12	Heating member for combination heating and chilling apparatus, and methods
GB2371557B (en)	2004-02-18	Method for the preparation of hydrogenated hydrocarbons
EP1328186A4 (en)	2006-03-22	METHODS OF TREATING VARIOUS EYES DISEASES
PL374215A1 (pl)	2005-10-03	Selektywne modulatory receptora estrogenowego
HUP0204526A3 (en)	2005-03-29	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
MXPA03004677A (es)	2003-09-05	Derivados de piperazina, su preparacion y su uso para tratamiento de trastornos del sistema nervioso central (snc).
PL368556A1 (pl)	2005-04-04	Sposoby leczenia albo zapobiegania chorobom skóryprzy zastosowaniu czynników wiążących CD2
AU5977501A (en)	2001-11-26	Method for treating retinal degeneration with purinergic receptor agonists
IL159570A0 (en)	2004-06-01	Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
MXPA03006607A (es)	2003-09-22	Metodo combinado para tratar trastornos dependientes de hormonas.
AU5289600A (en)	2000-12-12	4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands
WO2003039490A9 (en)	2013-11-14	Compositions and methods for diagnosing and treating mental disorders
ZA200205098B (en)	2004-03-31	Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
TWI320413B (en)	2010-02-11	1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
MXPA03006249A (es)	2003-09-22	Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.
MXPA03004195A (es)	2003-09-22	Terapia combinada para los trastornos dependientes de estrogenos.
IL164169A0 (en)	2005-12-18	Non-steroidal progesterone receptor modulators
ZA200209530B (en)	2004-02-23	Selective androgen receptor modulators and methods for their identification, design and use.
ZA200402285B (en)	2005-06-13	Ophthalmologic treatment methods using selective iNOS inhibitors.
ZA200504565B (en)	2006-08-30	1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system
AU2002358102A1 (en)	2003-07-09	Use of 7-monohydroxyethylrutoside for the treatment of haematological disorders, particurlarly beta-thalassemia
TW522868U (en)	2003-03-01	Wheel seat device for roller blades
HK1064050A (en)	2005-01-21	Methods for treating or preventing skin disorders using cd2-binding agents